Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Raymond James Reiterates Outperform on Dianthus Therapeutics, Raises Price Target to $63

Author: Benzinga Newsdesk | September 09, 2025 11:09am
Raymond James analyst Steven Seedhouse reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $56 to $63.

Posted In: DNTH

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist